Category: Accuray Inc.Syndicate content

Thoratec soars after killing it in Q3 | Earnings Roundup

February 9, 2012 by MassDevice staff

Thoratec shares gain big today after the heart pump maker reports more than 46% profit growth for the 4th quarter, lifting full-year earnings growth above 34%; also, Accuray soars on Q2 results; Hanger's Q4, 2011 profits soar; Cerner posts double-digit increases for Q4, 2011; Steris posts solid Q3 growth; Misonix swings to Q2 black; Q2 losses double for Cardiovascular Systems; Q2 sales slump, losses gape for pSivida; and DermaGraft sales trickle in for Shire.

Thoratec

Thoratec (NSDQ:THOR) shares are up more than 11% today after the heart pump maker put mid-double-digit profit growth numbers on the board for the 4th quarter and full-year 2011.

The Pleasanton, Calif.-based cardiac assist device maker logged profits of $15.3 million, or 25 cents per diluted share, on sales of $109.4 million for the 3 months ended Dec. 31, 2011. That's a 46.4% bottom-line gain and a top-line boost of 12.1%, compared with profits of $10.5 million, or 17 cents diluted EPS, on sales of $97.6 million during Q4 2010.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +7 | Synthes goes after Stryker, Oridion shares drop after import ban, FDA aims at reused med-tech, Accuray and Siemens amend ties, SNN spins out biologics unit, FDA releases December recalls and St. Jude expands in Plymouth

January 7, 2012 by MassDevice staff

The top seven medical device stories for the week of January 2, 2012.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

MassDevice.com +3 | Accuray and Siemens revamp agreements, Drug-eluters beat bare-metal stents in new study and GPO Premier rolls out a raft of new contracts

January 3, 2012 by MassDevice staff

The top three medical device stories for January 3, 2012.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Accuray and Siemens amend ties amid tough times

January 3, 2012 by MassDevice staff

Accuray amends a partnership to expand distribution rights for its newly acquired TomoTherapy's devices to Siemens.

Accuray logo
Siemens logo

Amid job losses and cost cutting measures, Accuray (NSDQ:ARAY) and Siemens AG (NYSE:SI) amended their strategic partnership to allow Siemens to sell CyberKnife products made by Accuray's recent acquisition, TomoTherapy Inc.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Accuray to cut workforce by 5%

November 16, 2011 by MassDevice staff

Accuray Inc. cuts 29 positions and plans to cut 22 more in order to reduce costs following its merger with TomoTherapy.

Accuray

Accuray (NSDQ:ARAY) laid off 29 workers and plans to cut another 22 over the next three quarters, reducing its workforce by 5 percent.

The cancer treatment device maker aims to reduce costs following its $277 million acquisition of TomoTherapy Inc. (NSDQ:TOMO).

Accuray dives despite beating The Street as losses gape | Earnings Roundup

November 9, 2011 by MassDevice staff

Accuray Inc.'s first-quarter results beat Wall Street's expectations, but investors still send its share price down 5 percent as the radiosurgery company's quarterly losses gape by more than 470 percent; also, results for CAS Medical Systems, Echo Therapeutics, CardioNet, Electromed, IntriCon, Bioject, Kips Bay Medical, Tornier, BioMimetic Therapeutics, Pro-Dex and Misonix.

Accuray

Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street's earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.

Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That's top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY's acquisition of rival TomoTherapy earlier this year.

Accuray dives despite beating The Street as losses gape

November 9, 2011 by MassDevice staff

Accuray Inc.'s first-quarter results beat Wall Street's expectations, but investors still send its share price down 5 percent as the radiosurgery company's quarterly losses gape by more than 470 percent.

Accuray

Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street's earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.

Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That's top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY's acquisition of rival TomoTherapy earlier this year.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp